References and resources

ANGIOLOGY/HAEMOSTASIS

• **HUG 2015: Drug-drug interactions, cytochromes P450 et P-glycoprotein (In French)
• ACCP 2012 : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed
• ACCP 2012 : Antithrombotic Therapy and Prevention of Thrombosis
• ACCP 2012 : Prevention of VTE in Nonorthopedic Surgical Patients
• ACCP 2012 : Prevention of VTE in Nonsurgical Patients
• ACCP 2012 : Prevention of VTE in Orthopedic Surgery Patients
• ACCP 2016: Update of Antithrombotic Therapy and Prevention of Thrombosis Guidelines, 9th ed
• ACCP 2018 : Antithrombotic Therapy for Atrial Fibrillation
• AFSSAPS 2009 : Prevention and treatment of venous thromboembolism in general medicine (In French)
• EHRA 2015: Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation
• EHRA 2018 Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
• EHRA 2018  Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
• ESC 2016 Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
• HAS 2015 : Place for oral anticoagulants (In French)
• HAS 2018 : Non valvular atrial fibrillation (In french)
• Juurlink D. Drug interactions with warfarin: what clinicians need to know. CMAJ 2007
• Kearon C, et al. Management of patients with hereditary Hypercoagulable disorders. Annu Rev Med 2000 [abstract]
• Nutescu E, et al. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 2011
• Schelleman H, et al. Fibrate/Statin Initiation in Warfarin Users and Gastrointestinal Bleeding Risk. Am Journal of Med 2010

CARDIOLOGY

• AAC : ASCVD score
• AACE 2017 Guidelines for management of dyslipidemia and prevention of cardiovascular disease
• ACC/AHA 2013 : Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
• ACC/AHA 2013 : Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
• ACC/AHA 2013: Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
• ACC/AHA 2017 Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults
• ACC/AHA/AATS/PCNA/SCAI/STS 2014 Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease 
• ACC/AHA/ESC 2006 : Management of Patients With Ventricular Arrhythmias
• ACC/AHA/HFSA 2017 Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
• ACCF/AHA 2013 : Guideline for the Management of ST-Elevation Myocardial Infarction
• ACCF/AHA 2013: Guideline for the Management of ST-Elevation Myocardial Infarction
• ACCF/AHA 2013 : Guideline for the Management of Heart Failure
• ACCF/AHA/ACP/AATS/PCNA/SCAI/STS 2012 : Management of Patients With Stable Ischemic Heart Disease
• ACCP 2012 : Antiplatelet Drugs. American College of Chest Physicians Evidence Based Clinical Practice Guidelines (9th Edition)
• ACCP 2012 : Antithrombotic and Thrombolytic Therapy for Ischemic Stroke
• AHA 2007 : Use of Nonsteroidal Antiinflammatory Drugs
• AHA/ACC 2014 : Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary
• AHA/ACC 2014 : Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndrome
• AHA/ASA 2012 : Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation
• AHA/ASA 2013 : Early Management of Patients With Acute Ischemic Stroke
• AHA/ASA 2014 : Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack
• AHA/ASA 2018 : Early Management of Patients With Acute Ischemic Stroke
• Akhtar N, et al. The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review Expert Opin. Ther. Patents 2011 [abstract]
• BMJ 2013 : cardiovascular events and sodium containing effervescent, dispersible, and soluble drugs
• CCSG 2012 : Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult
• DuBuske L. The Role of P-Glycoprotein and Organic Anion-Transporting Polypeptides in Drug Interactions. Drug Safety 2005 [abstract]
• ESC 2013 : Aspirin, still first-line in secondary prevention of cardiovascular complications in peripheral artery disease
• ESC 2015 : Acute Coronary Syndromes (ACS) in patients presenting without persistent ST-segment elevation (Management of)
• ESC 2015: Acute Coronary Syndromes (ACS) in patients presenting without persistent ST-segment elevation (Management of)
• ESC 2016 : Acute and Chronic Heart Failure
• ESC 2016 : Dyslipidaemias (Management of)
• ESC 2017 Focused update on Dual Antiplatelet Therapy (DAPT)
• ESC 2019 : Guidelines for the diagnosis and management of chronic coronary syndromes
• ESC/EAS 2019 : Guidelines for the management of dyslipidaemias
• ESC/EAS 2019: Guidelines for the management of dyslipidaemias
• ESC/ESH 2018 : Guidelines for the management of arterial hypertension
• European Association Preventive of Cardiologie : **HeartScore
• Framingham score
• HFSA 2010 : Comprehensive Heart Failure Practice Guideline
• HIV Pharmacovigilance : Framingham score adapted to patients with HIV
• HUG 2015 : Drug-drug interactions, cytochromes P450 et P-glycoprotein (In French)
• Joint National Committee (JNC 8) 2014 : Management of High Blood Pressure in Adults
• National Lipid Association 2014 Recommendations for Patient-Centered Management of Dyslipidemia
• NIH/ NHLBI 2004 : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
• PECH 2017 : Programme Éducatif Canadien sur l'Hypertension
• Prescrire le Guide. Avoid side effects due to drug-durg interaction ? (January 2013) (In French)
• Swiss Atherosclerosis Association : Score GSLA
• Vaclavik J, et al. Effect of Spironolactone in Resistant Arterial Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial (ASPIRANT-EXT)
• Valgimigli M, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012
• Varenhorst C, et al. Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. Eur Heart J 2013
•  AHA/ACC/HRS 2014 Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
•  ESC 2017 Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

DEPENDENCIES

• *Cage questionnaire
• *Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar)
• *rapid addiction detection tool such as the WHO-ASSIST*
• 2009 WHO Clinical guidelines for withdrawal management and treatment of drug dependence in closed settings
• 2011 NICE Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence
• AATOD Guidelines for addressing benzodiazepine use in opioid treatment programs (OTPs)
• ANAES/ SFA 1999: Objectives, indications and withdrawal of alcohol-dependent patients. Consensus Conference (In French)
• Anderson P, et al. Alcohol and Primary Health Care: Clinical Guidelines on Identi_cation and Brief Interventions. Department of Health of the Government of Catalonia: Barcelona 2005
• EMA 2010 : Overview of comments received on draft guideline on the development of medicinal products for the treatment of smoking
• Gian Pietro S, et al. Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol 2007 _abstract_
• GOLD 2019 : Diagnosis, management and prevention of COPD
• HUG 2010 : Alcohol Problem (In French)
• HUG 2010 : PharmaKit, Formation post-graduée en addictologie
• HUG 2010 : PharmaKit, Post-graduate training in addiction (In Frenc)
• OMS 2008 : The Effectiveness of a Brief Intervention for Illicit Drugs Linked to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in Primary Health Care Settings
• R. Saitz et al. Unhealthy alcohol use, clinical practice, NEJM, 2005
• SFA 2006 : Alcohol withdrawal (In French)
• Suboxone summary of product characteritics (2015)
• Wilby K, et al. Nicotine replacement therapy in the intensive care unit: a systematic review. J Intensive Care Med. 2014 [abstract]
• Yersin B, et al. alcohol withdrawal syndrome: Outpatient management by the general practitioner. Rev Méd Suisse romande 1998 (In French)

ENDOCRINOLOGY

• 2015 ATA : Guidelines for the Treatment of Hypothyroidis
• 2016 ATA : Hyperthyroidism and other causes of thyrotoxicosis management
• 2016 ESC CVD Prevention in Clinical Practice
• 2018 ADA/EASD Management of Hyperglycemia in Type 2 Diabetes
• ADA 2016 : Standards of Medical Care in Diabetes
• ADA 2019 : Standards of Medical Care in Diabetes
• ADA/ endocrine Society 2013 : Hypoglycemia and Diabetes
• ATA/ endocrine society/ AACE 2004 : Joint Statement on the U.S. Food and Drug Administration's Decision Regarding Bioequivalence of Levothyroxine Sodium
• Bach-Huynh TG, et al. Timing of Levothyroxine Administration Affects Serum Thyrotropin Concentration. JCEM 2009
• CDC 2013 : U.S. Selected Practice Recommendations for Contraceptive Use. Adapted from the WHO Selected Practice Recommendations for Contraceptive Use, 2nd Edition
• ESC 2016 : CVD Prevention in Clinical Practice
• ESC CVD Prevention in Clinical Practice
• ESC/ EASD 2013 : Diabetes, Pre-Diabetes and Cardiovascular Diseases developed with the EASD
• ESC/EASD 2019 : Guidelines on diabetes, pre-diabetes, and cardiovascular diseases
• F. Bosquet, et al. Endocrine and metabolic medication side effects. EMC - AKOS (Traité de Médecine) 2008 [abstract in French]
• Fish LH, et al. Replacement Dose, Metabolism, and Bioavailability of Levothyroxine in the Treatment of Hypothyroidism. NEJM 1987 [abstract]
• HAS 2014: drug strategy in type 2 diabetes (In French)
• Hassan Murad M, et al. Drug-Induced Hypoglycemia: A Systematic Review. J Clin Endocrinol Metab 2009
• Liwanpo L, et al. Conditions and drugs interfering with thyroxine absorption. Best Practice & Research Clinical Endocrinology & Metabolism 2009 [abstract]
• Moghadam-Kia S, et al. Prevention and treatment of systemic glucocorticoid side effects. International Journal of Dermatology 2010
• Sattar N, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010 [abstract]

GASTROENTEROLOGY

• **Assessment scales for the anticholinergic effects of drugs (In French)
• Abraham N, et al. Risk of Lower and Upper Gastrointestinal Bleeding, Transfusions, and Hospitalizations With Complex Antithrombotic Therapy in Elderly Patients. Circulation 2013
• ACCF/ACG/AHA 2008 : Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
• ACG 2014 : Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections
• Als-Nielsen B, et al. Nonabsorbable disaccharides for hepatic encephalopathy. BMJ 2004
• ASGE 2010 : The role of endoscopy in the management of patients with peptic ulcer disease
• Chandok N, et al. Pain Management in the Cirrhotic Patient: The Clinical Challenge. Mayo Clin Proc. 2010
• ESCMID 2009 : Data review and recommendations for diagnosing Clostridium difficile-infection
• HAS 2009: re-evaluation of proton pump inhibitors in adults (In French)
• Hepatoweb (In French)
• IDSA - SHEA 2017 : Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children
• Katz P, et al. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol 2013
• Kerdraon J, et al. Iatrogenic constipation. Pelvi-Périnéologie 2010 [abstract]
• Labos C, et al. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ 2011
• Laine L, et al. Management of Patients With Ulcer Bleeding. Am J Gastroenterol 2012
• Lanza FL, et al. Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol.2009
• Lewis JH, et al. Review article: prescribing medications in patients with cirrhosis. A practical guide. Aliment Pharmacol Ther 2013 [abstract]
• Livertox
• MELD score
• Rostom A, et al. Prevention of NSAID-induced gastroduodenal ulcers (reviews). Cochrane Database Syst Rev 2002 [abstract]
• Sharma P, et al. Disaccharides in the treatment of hepatic encephalopathy. Metab Brain Dis 2013 [abstract]

INFECTIOLOGY

• **Crediblemeds.org : List - All QTDrugs
• *Livertox
• *Modified Framingham score
• 2011 IDSA : Management of Community-Acquired Pneumonia in Adults
• 2012 INESS Intra-abdominal infections in adults (2012)
• 2017 NICE Guideline Tuberculosis
• 2018 NICE Guideline Urinary tract infection (catheter-associated) : antimicrobial prescribing
• AASLD 2018 Guidelines for Treatment of Chronic Hepatitis B
• AFSSAPS/SPILF/GPIP 2011: Focus on the proper injection of aminoglycosides: gentamicin, tobramycin, netilmicin, amikacin (In French)
• AIDSinfo 07.12.2015 : Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Voir section Drug-Drug Interactions [pages L1 à L49]
• AIDSinfo 25.12.2018 : Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Voir section Drug-Drug Interactions
• ASBMT 2009 : Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients
• ATS 2006 : Hepatotoxicity of Antituberculosis Therapy
• ATS/ CDC/ IDSA 2016 : Treatment of drug-Susceptible tuberculosis
• BSAC 2008 : Guidelines for the management of hospital-acquired pneumonia in the UK
• CDC 2013 : Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis
• CDC/ NIH/ HIVIAA 25.07.2017 : Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents
• EASC 2018 : European AIDS Cinical Society guidelines 9.1
• EASL 2017 : Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
• EASL 2018 : Recommendations on Treatment of Hepatitis C
• ESC 2015 : Infective Endocarditis (Guidelines on Prevention, Diagnosis and Treatment of)
• EULAR 2008 : recommendations for the management of primary small and medium vessel vasculitis
• Eyler R, et al. Antibiotic Pharmacokinetic and Pharmacodynamic Considerations in Patients With Kidney Disease. Advances in Chronic Kidney Disease 2010 [abstract]
• FDA Drug Safety Communication 2013 : Azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms
• HAS 2008 : Antibiotic therapy and prevention of bacterial resistance in healthcare organisations
• Hayashi Y, et al. Strategies for Reduction in Duration of Antibiotic Use in Hospitalized Patients. Clinical Infectious Diseases 2011
• hep-druginteractions.org (University of Liverpool)
• Hites M, et al. Case-Control Study of Drug Monitoring of Beta-Lactams in Obese Critically Ill Patients. Antimicrob. Agents Chemother 2013
• HIV-druginteractions.org
• HIV/HCV Medication guide
• HUG 2015: Drug-drug interactions, cytochromes P450 et P-glycoprotein (In French)
• IDSA 2010 : Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection in Adults
• IDSA 2013 : Diagnosis and Management of Prosthetic Joint Infection
• IDSA/ ASHSP/ SIDP 2009 : Vancomycin Therapeutic Guidelines: A Summary of Consensus Recommendations
• IDSA/ ESMID 2010 : International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women
• INESSS 2017 : Pneumonie acquise en communauté chez l'adulte
• Kiser J, et al. Review and Management of Drug Interactions With Boceprevir and Telaprevir. Hepatology 2012
• Manuel O, et al. Impact of standardised review of intravenous antibiotic therapy 72 hours after prescription in two internal medicine wards. J Hosp Infect 2010 [abstract]
• Morlat P, et al. Prise en charge médicale des personnes vivant avec le VIH recommandations du groupe d'experts rapport 2018
• NCCN 2012 :Prevention and Treatment of Cancer-Related Infections
• OMS 2010 : Treatment of tuberculosis Guidelines Fourth edition
• Owens R, et al. Antimicrobial stewardship: concepts and strategies in the 21st century. Diagnostic Microbiology and Infectious Disease 2008 [abstract]
• Pablos A, et al. Evaluation of an antibiotic intravenous to oral sequential therapy program. Pharmacoepidemiol Drug Saf 2005 [abstract]
• Pugh R, et al. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults (Review). The Cochrane Library 2011. [abstract]
• Ray WA, et al. Azithromycin and the Risk of Cardiovascular Death. N Engl J Med 2012
• Rotstein C, et al. Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. Can J Infect Dis Med Microbiol 2008
• SIS/ IDSA 2010 : Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children
• SPILF 2006 : 15th consensus conference about management of lower respiratory tract infections in immunocompetent adult (In French)
• Yale SH, et al. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome : associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996 [abstract]
• Zumla A, et al. Tuberculosis. NEJM 2013 [abstract]
•  Stern A, Green H, Paul M, et al. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2014

NEPHROLOGY

• *Site GPR: optimizing the proper use of medicines
• *The renal drug database:the Renal Drug Handbook in database format
• 2017 Update on AUA Guideline on the Management of Benign Prostatic Hyperplasia
• Fored M, et al. Acetaminophen, aspirin and chronic renal failure. NEJM 2001
• IDSA 2013 : Clinical Practice Guideline for Vaccination of the Immunocompromised Host
• KDIGO 2009 : Chronic Kidney Disease. Mineral and Bone Disorder
• KDIGO 2012 : Clinical Practice Guideline for Anemia in Chronic Kidney Disease
• KDIGO 2012 : Evaluation and Management of Chronic Kidney Disease
• KDIGO 2012 : Management of Blood Pressure in CKD
• Lord A, et al. La néphrotoxicité médicamenteuse. Le Médecin du Québec, 2002 (In French)
• Mebarki S, et al. Échelles d'évaluation de l'effet anticholinergique des médicaments. NPG 2012
• Perneger TV, et al. Risk of kidney disease associated with the use or acetaminophen, aspirin and nonsteroidal antiinflammatory drugs. NEJM 1994
•  KDIGO 2017 : Chronic Kidney Disease. Mineral and Bone Disorder Udapte

NEUROLOGY

• *HUG 2015: Drug-drug interactions, cytochromes P450 et P-glycoprotein (In French)
• 2017 NICE guidance : Managing symptoms of Parkinson’s disease
• 2017 NICE guidance : Parkinson’s disease in adults
• Aminoff MJ, et al. Management of the hospitalized patient with Parkinson's disease: Current state of the field and need for guidelines. Parkinsonism Relat Disord. 2011
• Brennan KA, et al. Managing Parkinson's disease during surgery. BMJ 2010 [abstract]
• Desfossés C, et al. Drugs that lower the seizure threshold. Le Médecin du Québec 2002 (In French)
• Emergency management of patients with Parkinson's
• Get It On Time campaign 2010 : Going into Hospital
• Hantson P. Toxic seizures. Réanimation 2004 (Mise au point) (In French)
• ILAE 2008 : Antiepileptic drugs best practice guidelines for therapeutic drug monitoring
• Jones SL, et al. Parkinson's disease in the acute hospital. Clinical Medicine 2011
• Katz M et al., Top Ten Tips Palliative Care Clinicians Should Know About Parkinson's Disease and Related Disorders 2018
• Patsalos P, et al. The importance of drug interactions in epilepsy therapy. Epilepsia 2002
• Product caracteristics : Dompéridone (In french)
• Public Health England 2013 : Guidelines for malaria prevention in travellers from the UK
• WHO 2009 : Medical eligibility criteria for contraceptive use – 4th ed
•  Katz M et al., Top Ten Tips Palliative Care Clinicians Should Know About Parkinson's Disease and Related Disorders 2018

OBESITY

• ACCP 2012 : Antithrombotic Therapy and Prevention of Thrombosis (9th Edition)
• AHSP/ IDSA/ SIDP 2010 : Therapeutic Monitoring of Vancomycin in Adult Patients
• Cockshott P, et al. Intramuscular or intralipomatous injections. NEJM 1982 [abstract]
• Nutescu E,et al. Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings. Ann Pharmacother 2009

OPHTHALMOLOGY

• 2017 NICE Glaucoma: diagnosis and management
• Razeghinejad MR, et al. Iatrogenic Glaucoma Secondary to Medications. The American Journal of Medicine 2011 (review)

PAIN and ANALGESIA

• 2013 NICE Neuropathic pain in adults: pharmacological management in non-specialist settings
• AAN 2000 : Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
• AAN/ AANEM/ AAPMR 2011 : Treatment of painful diabetic neuropathy
• AAN/AHS 2012 : Evidence based guideline update: pharmacologic treatment for episodic migraine prevention in adults
• AAN/AHS 2012 [CORRECTION] : Evidence based guideline update: pharmacologic treatment for episodic migraine prevention in adults
• Antonaci F, et al. A review of current European treatment guidelines for migraine. J Headache Pain 2010
• ASIPP 2012. Opioid Prescribing in Chronic Non-Cancer Pain: Part 2 : Guidance
• British Association for the study of headache 2010 : Diagnosis and Management of Migraine, Tension-Type Headache, Cluster Headache, Medication-Overuse Headache
• Canadian Pain Society, 2002 : Use of opioid analgesics for the treatment of chronic noncancer pain
• Chaparro LE, et al. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev. 2012 [abstract]
• Chou R, et al. Opioid Treatment Guidelines : Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain. J Pain 2009
• Consensus Recommendations on Initiating Prescription Therapies for Opioid-Induced Constipation
• EFNS 2010 : Pharmacological treatment of neuropathic pain. European Journal of Neurology 2010
• Fine P et al. Best practice for opioid rotation : conclusion of an expert panel. J Pain and sympt manag 2009 [abstract]
• Hollande S, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults. Neurology 2012
• IHS 2013 : The International Classification of Headache Disorders, 3rd edition.Cephalalgia 2013
• Moulin DE, et al. Pharmacological management of chronic neuropathic pain: Revised consensus statement from the Canadian Pain Society Pain Res Manage 2014
• NICE 2013 : Neuropathic pain: pharmacological management: The pharmacological management of neuropathic pain in adults in non-specialist settings
• O'Connor A, et al. Treatment of Neuropathic Pain: An Overview of Recent Guidelines. The Am J Med 2009 [Abstract]
• Pereira J, et al. Equianalgesic Dose Ratios for Opioids: A Critical Review and Proposals for Long-Term Dosing. J Pain Symptom Manage 2001
• Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev 2004 [abstract]
• Roulet L, et al. Opioid rotation : from theory to practice. Interdisciplinary guidelines from the Geneva University Hospitals pain network. Rev Med Suisse 2011 (In French)
• Sarthe Pain Network. Guide for strong opioids use in clinical practice. (In French)
• Société suisse pour l'étude des céphalées 2019 : Céphalées et algies faciales Recommandations thérapeutiques
• WHO 1996 : Cancer pain relief, second edition

PHARMACOLOGY AND TOXICOLOGY

• *ANSM Drug and G6PD deficiency: updating the repository - Information Point (In French)
• *G6PD deficiency Association - favism: Drugs that should be avoided - Official List
• *HUG 2015 : Drug-drug interactions, cytochromes P450 et P-glycoprotein (In French)
• 2014 International Consensus (ICON): Drug allergy – Position paper 
• ANSM 2014 : Médicaments et déficit en Glucose-6-Phosphate Déshydrogénase (G6PD). Classement des médicaments par substance active
• Birmes P, Coppin D, Schmitt L, Lauque D. Serotonin syndrome: a brief review. CMAJ 2003
• Boyer E, et al.The Serotonin Syndrome. NEJM 2005
• Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet 2008; 371:64.
• Crediblemeds : All QTDrugs
• F. Bourdaina, M. Tir b, J.-M. Trocello, Mise au point, Les syndromes parkinsoniens : de l’analyse sémiologique au diagnostic nosologique. La revue de médecine interne 2017
• Lopez-Sendon J, et al. Drug-induced parkinsonism. Expert Opin. Drug Saf. 2013 [abstract]
• Rodolfo Savica, Brandon R. Grossardt, James H. Bower, J. Eric Ahlskog, Michelle M. Mielke, Walter A. Rocca, MPHIncidence and time trends of drug?induced parkinsonism : A 30?year population?based study, Movement Disorders, 2017.
• Summary of products characteristics folinic acide (In French)
• Walling J. From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs 2006; 24:37.

PNEUMOLOGY

• GINA 2018 : Global Strategy for Asthma Management and Prevention
• HUG 2017  Chronic obstructive pulmonary disease (In french)
• Lee MK, et al. The Efficacy of Immediate Diet for Reducing Local Adverse Events of Inhaled Corticosteroid: A Pilot Study. Tuberc Respir Dis 2012
• NHLBI/NIH 2007 : Guidelines for the Diagnosis and Management of Asthma
• NICE 2017 Asthma : diagnosis, monitoring and chronic asthma management
• NICE 2018 Chronic obstructive pulmonary disease in over 16s
• NICE 2018 Chronic obstructive pulmonary disease in over 16s : diagnosis and management

PSYCHIATRY

• APA 2010 : Treatment of Patients With Major Depressive Disorder
• NICE 2009 : Depression in adults: recognition and management
• NIH 2005 : Manifestations and Management of Chronic Insomnia in Adults
• Schutte-Rodin S, et al. Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults. Journal of Clinical Sleep Medicine 2008
• WFSBP 2012 : Guidelines for Biological Treatment of Schizophrenia, Part 2
• WOH 2011 mhGAP Intervention Guide for mental, neurological and substance use disorders in non-specialized health
• WOH 2011 mhGAP Intervention Guide for mental, neurological and substance use disorders in non-specialized health settings

RHEUMATOLOGY

• **FRAX: Fracture Risk Evaluation Tool
• ACR 2008 : Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
• ACR 2012 : Management of Gout Part I
• ACR 2012 : Management of Gout Part II
• ACR 2012 : Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis
• ACR 2017 : Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis
• ASBMR 2009 Bisphosphonate?Associated Osteonecrosis of the Jaw: Report of a Task Force
• Benhamou CL, et al. Vitamin D in adults: GRIO guidelines. Press Med 2011 (In French)
• EULAR 2006 : evidence based recommendations for gout. Part II: Management
• EULAR 2011 : recommendations for calcium pyrophosphate deposition. Part II : Management
• EULAR 2013 : management of medium to high-dose glucocorticoid therapy in rheumatic diseases
• EULAR 2013 : management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
• EULAR 2016 Recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
• Ho J, et al. Considerations when prescribing trimethoprim/sulfamethoxazole. CMAJ 2011
• I. Reid, Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies 2012
• Khanna D, Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies, Arthritis Rheum. 2005 Oct
• NHLBI/NIH 2007 : Guidelines for the Diagnosis and Management of Asthma
• Richette P, et al. Gout (review). Lancet 2010 [abstract]
• Richette P, et al. Gout. Lancet 2010 [abstract]
• Roddy E, et al. Epidemiology of gout. Arthritis Research & Therapy 2010
• Shea B, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis (Review). Cochrane 2013 [abstract]
• Updated EULAR 2016 evidence-based recommendations for the management of gout
•  ACR 2015 Guideline for the Treatment of Rheumatoid Arthritis

TRANSPLANTS

• **HUG 2015 : Drug-drug interactions, cytochromes P450 et P-glycoprotein (In French)
• ACCP 2011 : Pulmonary Complications of Lung Transplantation
• AST/ ASTS 2009 : Long-term Management of the Liver Transplant Patient: Recommendations for the Primary Care Doctor
• ISHLT 2010 : Guidelines for the care of heart transplant recipients
• ISHLT 2010 :Guidelines for the care of heart transplant recipients
• KDIGO 2009 : Clinical practice guideline for the care of kidney transplant recipients. American Journal of Transplantation
• KDIGO 2009 :clinical practice guideline for the care of kidney transplant recipients. American Journal of Transplantation

VACCINATIONS

• ACCR 2015 : Guideline for the Treatment of Rheumatoid Arthritis
• ACCR 2015 : Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis
• Calendrier vaccinal et recommandations vaccinales 2018 France
• CDC : Prevent Seasonal Flu
• CDC/ ACIP 2012 : Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions
• Danzinger-Isakov L, et al. Guidelines for Vaccination of Solid Organ Transplant Candidates and Recipients. Am J Transplant 2009
• Infovac Suisse 2018 (In french)
• Jacobs J, et al. Biometric fingerprinting for visa application: device and procedure are risk factors for infection transmission. J Travel Med 2008
• Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007;34:272–9
• KDIGO 2012 :Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
• Quebec Immunization Protocol (In French)
• Vacc.info Belgique (In French)

This site complies with the HONcode standard for trustworthy health information: verify here.